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ABSTRACT

A method, system, and kit are provided for diagnosing L.
intracellularis infection or exposure in a subject. The method
includes purifYing whole L. intracellularis from host cells
and host debris produced in or on a suitable medium and
adhering the purified whole L. intracellularis on a suitable
material to form an antigen substrate for determining whether
a subject produces L. intracellularis-specific antibodies
against the antigen to thereby indicate L. intracellularis exposure or infection in the subject. The kit includes purified
whole L. intracellularis produced from host cells and host
debris adhered to a suitable material to form an antigen substrate adapted for screening serum from a subject. A method
for diagnosing L. intracellularis exposure or infection in a
subject includes acquiring a serum sample from a subject,
introducing the serum sample to an antigen substrate followed by detecting a presence of L. intracellularis-specific
antibodies in the serum.
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METHOD AND SYSTEM FOR DIAGNOSIS OF
LAWSON/A INTRACELLULARIS

Enzyme-linked immunosorbent assay (ELISA) for detection of L. intracellularis-specific antibodies have been previously developed for the pig and rabbit (Watarai et a!. 2004;
Boesen eta!. 2005; Kroll eta!. 2005; Wattanaphansak eta!.
2008).

CROSS REFERENCE TO RELATED
APPLICATIONS

SUMMARY OF THE INVENTION

This application claims the benefit of Provisional Application Ser. No. 61/560,275, filed Nov. 15, 2011 herein incorporated by reference.
10

FIELD OF THE INVENTION
The presently-disclosed subject matter relates to methods
and systems for use in the diagnosis of Lawsonia intracellularis infection in a subject. In particular, the presently-disclosed subject matter relates to an enzyme-linked immunoabsorbent assay (ELISA) for diagnosing Lawsonia
intracellularis infection and exposure in a subject.
BACKGROUND OF THE INVENTION
Exposure to pathogens cause illness and even death to
living organisms such as humans, animals and plants. There
are numerous techniques used to diagnose pathogen infections and exposure.
One pathogen of importance to mammals is the bacterium,
L. intracellularis. L. intracellularis is an obligate intracellular, Gram-negative rod, is the causative agent of proliferative
enteropathy (Lawson and Gebhart 2000). L. intracellularis is
viewed as an emerging cause of proliferative enteropathy in a
variety of mammalian species (Drolet eta!. 1996; Hotchkiss
eta!. 1996), including horses (Williams eta!. 1996; Cooper et
a!. 1997; Frank et a!. 1998; Brees et a!. 1999), where the
bacteria causes equine proliferative enteropathy (EPE).
Clinical signs of EPE, usually seen in weanlings or young
yearlings (Frank eta!. 1998; Brees eta!. 1999; Lavoie eta!.
2000; Schumacher et a!. 2000; Frazer 2008), include anorexia, fever, lethargy, depression, peripheral edema caused by
hypoproteinemia/hypoalbuminemia, weight loss, colic and
diarrhea. In addition, thickened small intestine detected by
abdominal ultrasound is considered highly suggestive ofEPE
when accompanied by compatible clinical signs. Commercially available ante mortem tests for EPE include fecal L.
intracellularis-specific polymerase chain reaction (PCR) and
the serum immunoperoxidase monolayer assay (IPMA), both
of which have been adapted from their use in pigs where the
tests are highly specific; sensitivity is reported to be high for
the IPMA (Guedes eta!. 2002a,b) but variable for faecal PCR
(Herbst eta!. 2003; Jacobson eta!. 2004).
Although the epidemiology of EPE is uncertain, it is
believed that transmission occurs through the ingestion of L.
intracellularis-contaminated fecal material from wild or
domestic animals (Pusterla eta!. 2008b ). While most cases of
EPE typically occur in the fall and early winter (Frazer 2008;
Page et a!. 2011 b), the reason for this seasonal predilection
has not yet been determined. One possibility is the known
susceptibility of weanlings to this infection and weaning typically occurs during this time of year (Frazer 2008). Another
possibility would be that the environmental conditions at that
time favor transmission by increasing exposure burdens.
Previous work on the detection of L. intracellularis-specific antibodies on specific farms demonstrated seroprevalences ranging from 33.8 to 45.5% on two California farms
(Pusterla et a!. 2008a) and up to 60% on a Kentucky farm
(Page eta!. 2011 b), utilizing the IPMA method. A large scale,
recent study, detailed within, found that seroprevalence on
some equine farms actually approaches 100%.
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The present invention is directed to a novel method for
detecting the presence of Lawsonia intracellularis-specific
antibodies for the diagnosis of Lawsonia intracellularis
exposure or infection. The present method and system may
also be used for evaluating the efficacy of a vaccine. The
presently disclosed subject matter overcomes sensitivity and
specificity issues associated with prior techniques for evaluating Lawsonia intracellularis exposure and infection including those described above in the Background of the Invention
section. The present method and system can be used for
subjects including but not limited to farm animals, such as
horses (including race horses) and swine.
One unique aspect of the present method and system for
detecting Lawsonia intracellularis exposure or infection
includes a process in which whole L. intracellularis cells, are
purified for use as an antigen in the ELISA. As a result, the
present method and system uses whole purified Lawsonia
intracellularis in contrast to prior techniques which are
directed to identifying the presence of a Lawsonia intracellularis amongst host cells and host cell debris due to a lack of
complete purification of the L. intracellularis. In various specific forms of the present method and system, the purified L.
intracellularis, e.g. bacteria, is a chromatography-purified
whole L. intracellularis. As will be recognized by those of
ordinary skill in the art, it can be useful to monitor a particular
subject over time using the methods and systems described
herein, i.e., conducting multiple diagnostic tests at different
time points.
The present invention, in one form thereof, relates to a
method for diagnosing L. intracellularis exposure or infection in a subject. The method includes acquiring a blood
sample from a subject and processing that blood sample using
centrifugation which separates serum from whole blood cells
to form an isolated sample. The isolated sample is analyzed
for the presence ofL. intracellularis-specific antibodies using
an ELISA and the subject is diagnosed as having a L. intracellularis infection or exposure if the presence of L. intracellularis-specific antibodies are detected when analyzing the
isolated sample. For analysis of the isolated sample, L. intracellularis whole cells are processed and purified using centrifugation followed by chromatography.
The present invention, in another form thereof, relates to a
method for evaluating effectiveness of a vaccine against a L.
intracellularis infection in a subject. The method includes
administering a test vaccine to a subject and subsequently
acquiring a blood sample from the subject. The blood sample
is processed using centrifugation which separates serum from
whole blood cells form an isolated sample. The isolated
sample is analyzed for presence of L. intracellularis-specific
antibodies. The vaccine is determined to be effective at eliciting an immune response if L. intracellularis-specific antibodies are detected when analyzing the isolated sample and
the subject does not exhibit symptoms of L. intracellularis
infection or signs of clinical disease.
In one further specific form of the method for evaluating
effectiveness of a vaccine, the method further includes exposing a subject to a L. intracellularis after the vaccine has been
administered to the subject and the subject has had sufficient
time to develop an immune response to the vaccine but before
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acquiring the blood sample from the subject. Effectiveness of
the vaccine is determined if the subject blood sample has
detectable amounts of L. intracellularis-specific antibodies
and remains free of signs of clinical disease.
The present invention, in another form thereof, relates to a
method for diagnosing L. intracellularis infection or exposure in a subject. The method includes purifying whole L.
intracellularis from host cells and host debris produced in or
on a suitable medium. The purified L. intracellularis is
adhered on a suitable material to form an antigen substrate for
determining whether a subject produces L. intracellularis
specific-antibodies against the antigen and thereby indicate a
L. intracellularis exposure or infection in the subject.
The pathogen may be purified from host cells and host
debris using centrifugation followed by ion-exchange chromatography. The suitable material upon which the purified L.
intracellularis is adhered may be an enzyme-linked immunosorbent assay (ELISA) plate. In one specific form, the
method may include introducing a serum sample from a subject to the antigen substrate to determine whether the serum
contains L. intracellularis-specific antibodies against the
antigen. The serum may be produced from centrifugation of a
blood sample taken from the subject.
The present invention, in another form thereof, relates to a
kit for diagnosing pathogen infection or exposure in a subject.
The kit includes purified, whole pathogen adhered to a suitable material to form an antigen substrate. The antigen substrate is adapted to be used to screen serum from a subject for
L. intracellularis-specific antibodies against the antigen, to
thereby indicate L. intracellularis exposure or infection in the
subject. Advantageously, the purifiedL. intracellularis is produced by centrifugation of pathogen host cells and host debris
followed by ion-exchange chromatography. Further, in one
specific form, a suitable material is an ELISA plate.
The present invention, in another form thereof relates to a
method for diagnosing L. intracellularis infection or exposure in a subject. The method included acquiring a serum
sample from a subject and introducing the serum sample to an
antigen substrate comprising purified L. intracellularis
adhered to a suitable medium. The purified L. intracellularis
is produced from host cells and host debris. Presence of L.
intracellularis-specific antibodies are detected in the serum
against the antigen substrate, thereby indicating pathogen
exposure or infection in the subject.
Exemplary conditions and reagents that can be used in
some embodiments of the present method and system include
the ELISA methods disclosed herein. A carbonate buffer can
be used as a coating buffer. The antigen can be provided at a
concentration of about 2.5 micrograms/ml, and the plate/
antigen can incubate overnight at about 4 degrees C. PBS with
Tween can be used as the ELISA wash, and polyvinyl alcohol
can be used as the blocking buffer. The sample serum dilution
can be about 1:100, and the sample incubation can be at room
temperature for about 1 hour. The antibodies can be mouse
anti-horse conjugated with HRP, and the anti IgG incubation
can be at room temperature for about 1 hour in the dark. In
some embodiments anti-IgM can be used. The substrate can
be TMB (3,3',5,5'-tetra-methylbenzidine). A standard curve
can be generated from known IPMA titer, and ELISA units
(EU) can be determined on a continuous scale, allowing for a
sensitive and specific measurement. The ELISA procedure
can be modified to incorporate other species-specific reagents
such that the ELISA can test samples originating from a
variety of other species including, but not limited to, swine,
hamsters, rabbits, mice, rats, non-human primates, humans,
raccoons, birds and insects. It is important to note that the
present ELISA can be easily adapted for use in a variety of

other species (i.e. not just horses), which will be readily
apparent to those of ordinary skill in the art.
BRIEF DESCRIPTION OF THE DRAWINGS
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FIG. 1 is a plot relating enzyme-linked immunosorbent
assay (ELISA) units (EU) values for nonchallenged weanling
controls and L. intracellularis-challenged weanlings as well
as clinical EPE cases in which dashed bar represents 55 EU,
of the cut-off for positive samples.
FIG. 2 is a plot relating ELISA units to weanlings overtime
in which all studied time points from those weanlings
remained seronegative (<55 Enzyme-linked immunosorbent
assay (ELISA) units (EU) for the entire study and those that
seroconverted at any point;;,;55 EU) during the study period.
Each colunm for the study horses represents an individual
horse. Dashed bar represents 55 EU.
FIG. 3 is a graph depicting monthly percentage of previously seronegative horses that seroconverted (55 Enzymelinked immunosorbent assay (ELISA) units ((EU) or greater)
during a given month and total number of seropositive horses.
FIG. 4 is a chart depicting monthly distribution of positive
enzyme-linked immunosorbent assay (ELISA) results
reported as ranges of ELISA units (EU).
FIG. 5 is a plot showing monthly seroconversions for
groups (confirmed, suspected, none) of farms based on recent
equine proliferative enteropathy (EPE) history.
DETAILED DESCRIPTION
The present method and system will now be described with
reference to specific experiments demonstrating the efficacy
of the present method and system in diagnosing L. intracellularis infection or exposure. However, the following
examples and experiments do not limit the scope of the
present disclosure and variations to the methods and experiments described below can be modified in accordance with
the understanding of one of ordinary skill in the art.
Materials and Methods
Farm Selection and Information Gathering
A total of 25 Thoroughbred farms were recruited for participation in a study using various methods to test efficacy of
the present methods. Farms provided information regarding
EPE cases in the preceding 3 years. These data were used to
classify farms as either having confirmed cases of EPE, suspected but unconfirmed cases of EPE, or no recent cases of
EPE. Farms were considered to have had confirmed EPE
cases if they had one or more weanlings with clinical signs
compatible with EPE, hypoproteinaemia and hypoalbuminemia, and either a concurrent positive faecal PCR or serum
IPMA titer result (1:60 or greater) in the preceding 3 years.
For the purpose of this study, compatible clinical signs for
EPE were anorexia, fever, lethargy, depression, dependent
edema, rapid weight loss, colic and diarrhea. Farms were
considered to have had suspected EPE cases if they had one or
more weanlings with signs compatible with EPE, but neither
a positive faecal PCR nor positive serum IPMA titer result
(1:60 or greater). Farms were considered to have had no
recent history of EPE if there were no horses with clinical
signs ofEPE within the preceding 3 years.
After the conclusion of the study, all participating farms
were requested to complete a questionnaire regarding EPE
cases on the farm during the study period. Based on this
information, farms were classified for the study period into
the 3 categories as above.
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Study Period
The study period began Aug. 16, 2010 and concluded Jan.
5, 2011. For some farms, an optional sample collection period
from 31 Jan. to 2 Feb. 2011 was included in the study due to
a large increase in the number of seropositive samples in
January. Samples were collected from the farms once during
a 3 day period every 4 weeks.
Horses
Although some farms housed non-Thoroughbred horses,
only Thoroughbred horses were included in the study. All
horses in the study were born during the 2010 foaling season
and weaned by November 2010. Farms were requested to
provide a list of all 2010 horses present on the farm in early
August 2010. If a farm had 14 or fewer 2010 horses at this
time, all horses were included in the study. For those farms
with 15 or more horses present in early August, 15 horses
were chosen randomly to participate (except for Farm 19,
from which all 16 horses were included in the study at the
farm's request). Randomization was achieved by assigning
each horse a sequential number and utilizing a random number generator (Microsoft Excel) to select the 15 horses for
inclusion in the study. Each horse included in the study was
assigned a unique 3 digit identification number for ease of
results tracking, as well as maintaining anonymity.
Sample Collection and Handling
Once every 4 weeks, a 10 ml sample of whole blood was
collected into individually labeled, sterile, red-top 10 ml
blood tubes via jugular venipuncture. Samples were submitted and held at centralized laboratories at 4 o C. for less than 24
h before they were collected and transported to the Maxwell
H. Gluck Equine Research Center at the University of Kentucky. Upon arrival, samples were immediately centrifuged at
800xg for 10 min. Serum was transferred to tubes labeled
with the month and a unique 3 digit code assigned to its horse
and frozen at -20° C. until analyzed.
For various reasons, including public sale, private sale or a
horse being returned to its owner, a number of blood samples
were omitted from the study. As such, data from any horses
that left the study prior to November were completely
excluded from the data set. Horses remained in the study even
if one or more samples were not collected after October.
Serum samples obtained from 6 Lawsonia intracellularischallenged weanlings and 15 uninfected controls were
included for the validation of the ELISA, with information
regarding the challenge reported elsewhere (Page et a!.
2011a).
Lawsonia intracellularis-Specific Immunoperoxidase
Monolayer Assay
The IPMA method for determining L. intracellularis-specific antibody titers was performed as previously described
(Guedes eta!. 2002b ).
Purification of L. intracellularis
L. Intracellularis is purified using centrifugation and ionexchange chromatography. Generally speaking ion-exchange
chromatography involves the process of separating polar
(charged) materials (compounds, particulates, etc.) on the
basis of the charges carried by solute molecules. Materials to
be separated are adhered to the reversibly charged insoluble
matrix of the exchange material and then sequentially eluted
by altering either the solvent pH or ionic concentration. In this
specific case DEAE serves as the ion exchange media to
which the centrifuged bacteria is adhered and then purified by
elution with increasing buffer salt (NaCI) concentrations.
Specifically, the bacteria are initially isolated from cellular
debris initially by low speed centrifugation (400-600xg) to
remove cellular debris followed by high speed centrifugation
(6,500xg) to pellet the bacteria. The bacteria, suspended in

0.01 M. Phosphate buffer, is applied to a low pressure liquid
chromatography colunm (2.5 cmx30 em) containing DEAESepharose CL-6B equilibrated with 0.01 M. Phosphate
buffer, pH 6.8. The colunm is washed with 5 volumes of0.01
M. Phosphate buffer, pH 6.8. The buffer is then changed
sequentially to 0.01 M. Phosphate buffer, pH 6.8 with 0.1 M
NaCI, 0.01 M. Phosphate buffer, pH 6.8 with 0.15 M NaCI,
and 0.01 M. Phosphate buffer, pH 6.8 with 0.2 M NaCI and
the eluted protein peaks collected. The eluted material is
concentrated by centrifugation (6,500 g for 60 minutes at 4°
C.) if necessary and resuspended in PBS with 0.02% NaN3 .
Referring now to one specific purification process, porcine-origin L. intracellularis was obtained from cell culture
(Lawson et a!. 1993) and purified using diethy laminoethy I
(DEAE) colunm chromatography, which allowed the bacterium to be eluted as a whole organism. The presence of L.
intracellularis in the eluate was verified microscopically
using Gimenez stain, in addition to PCR for L. intracellularis,
as previously described (Jones eta!. 1993). Additionally, no
other bacteria were present following aerobic and anaerobic
culture, as well as Gram staining. The pooled purified bacterial eluate with sodium azide was kept refrigerated (4° C.).
Quantification of the purified bacterial protein performed
using the bicinchoninic acid (BCA) method (Sorensen and
Brodbeck 1986).
Lawsonia intracellularis-Specific Enzyme-Linked Immunosorbent Assay
The ELISA was based on previously described methods
(Wattanaphansak eta!. 2008) with respect to starting concentrations of reagents and a checkerboard titration scheme, as
described elsewhere (Kroll eta!. 2005; Wattanaphansak eta!.
2008). Factors influencing background were minimized
using previously described methods (Wattanaphansak et a!.
2008). From this, it was found that serum dilutions of 1:100
produced the most consistent results with minimal background. Further, based on this approach, the optimum concentration of antigen was 2.5 flg/ml and the use of a polyvinyl
alcohol block was superior to 5 or 10% skim milk.
The ELISA plates (Immunolon 1b Flat Bottom Microtiter
plates) were coated with 2.5 flg/ml of purified L. intracellularis in carbonate buffer, then covered with Parafilm-M and
allowed to sit overnight at 4 o C. After plates incubated overnight, they were washed 3 times with phosphate-buffered
saline with 0.05% Tween-20 (PBST) using an ELISA plate
washer (MW 96/384 ). The coated plates were then blotted dry
before adding 200 fll/well of blocking buffer (polyvinyl alcohol [Mowiol 6-98] 1% [w/v] in distilled water) for 1 hour at
room temperature. After blocking, the plates were washed 3
times, as above. Sera were diluted at 1:100 in blocking buffer
and added (1 00 fll) to duplicate wells. Plates were then incubated at room temperature for 1 h. Duplicate, serially diluted
(1 :60 through 1:3840) serum samples from a weanling exhibiting clinical signs compatible with EPE, including anorexia,
weight loss and dependentedema, was used to generate a
standard curve. This weanling tested positive repeatedly at
1:1920 using the IPMA method. Negative control samples
included serum from repeatedly L. intracellularis antibodynegative weanlings along with a duplicate sample of 100 fll
fetal equine serum diluted 1:100. After 1 h incubation with
diluted test and control sera, the plate was washed 3 times and
100 ml of murine anti horse IgG (1:4000) conjugated with
horseradish peroxidase (HRP) was added to each well. The
plate was then incubated in the dark for 1 hat room temperature before being washed 3 times. To each well was then
added 100 fll of3,3',5,5'-tetra-methylbenzidine (TMB) solution (SureB!ue TMB Microwell Peroxidase substrate) for 2
min before the reaction was stopped with TMB Stop solution.
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Absorbance at 450 run was read within 5 min using an ELISA
plate reader (Benchmark plus). Results from the test sera
were converted to ELISA units (EU) utilizing a linear trend
line from the standard curve generated from each plate. A
coefficient of determination (r) oh0.90 was required for the
plate to be considered valid (Kroll et a!. 2005).
A positive cut -off of 55 EU or greater was utilized based on
nonchallenged weanlings having an average of 33 EU and a
standard deviation of7 EU (Page eta!. 2011a); these samples
repeatedly tested negative via IPMA. By setting the cut-off at
55 EU, this value is 3 s.d. units above the negative control
averages and represents the upper limit of a 99% confidence
interval.
Evaluation of Assay Repeatability
Twenty-four samples were selected for the ELISA repeatability test. These represented a variety of negative (<55 EU),
low (55-119 EU), mid (120-239 EU) and high (-240 EU)
samples. For intra-assay repeatability, 3 replicates of each
sample were performed on the same plate. For inter-assay
repeatability, 3 replicates of each sample were run on duplicate plates on different days. Coefficient of variation
(CV=s.d./meanx100%) of the 3 replicates from each test
were evaluated. In addition, CV's of the standard curve optical densities (ODs) from each plate was evaluated.
Data Analysis
Farms 8 and 9 were ultimately considered as one farm data
set since the horses from these 2 farms were combined into
one population once the foals were weaned. Likewise, Farms
22 and 23 were combined into one data set for the same
reason.
One way analysis of variance (ANOVAs) (Holm-Sidak
method) was used to evaluate differences in ELISA titers
between farms categorized based on their past EPE status.
Post hoc t tests were performed to evaluate the differences
between groups. Chi-square analyses were used to assess
seroprevalence results. Calculated P valuess0.05 were considered to be statistically significant.
Results
In order to validate our ELISA, serum samples of varying
EU were run in triplicate with an overall intra-assay CV of
6.73 and inter-assay CV of9.60. For the standard curve, CVs
ranged from 2.08 to 7.69 with a mean of 4.85 and the most
dilute sample (1 :3840 dilution) had the highest CV. Additionally, ELISA analysis of serial serum samples from L. intracellularis challenged weanlings demonstrated seroconversion
on or before Day 20 post challenge with all weanlings obtaining EU> 120 and a maximum of 7 46 EU while all nonchallenged weanlings remained below 55 EU (Page eta!. 2011a).
Provided in FIG. 1 are EU results for nonchallenged controls and experimentally challenged weanlings (Page et a!.
2011a), as well as clinically affected field cases from the
study period (EU values shown are those found at the initial
time of clinical presentation). Weanlings with clinical EPE
had similar and, in some cases greater, serum antibody levels
against L. intracellularis when compared with experimentally challenged weanlings. FIG. 2 includes EU results from
all horses in the present study divided into 2 groups; study
horses that failed to seroconvert (<55 EU) during the study
and study horses that seroconverted (;;:55 EU) at any point
during the study period but failed to show clinical signs of
EPE. A number of the nonclinical, seropositive horses exhibited very high EU.
Overall, a total of 337 horses were included in the seraprevalence data set as they were present on the farms through
at least November 2010. Of these 337 horses, a total of 229
horses or 68.0% of the study population, tested positive (;;:55
EU) for L. intracellularis-specific antibodies via the ELISA

at one or more time points. The monthly percentage of previously seronegative horses that seroconverted during a given
month and the accruing totals are shown in FIG. 3. Overall,
there was a steady increase in the number of seropositive
horses over time
TABLE 1
Seroprevalence by farm according to previous EPE history and
equine proliferative enteropathy (EPE) status during the study period

10

History
of
previous
EPE cases

2010
foaling
season
EPE cases

Total
ELISA
positive
horses

No
No
Confirmed
No
No
Confirmed
No
No
Confirmed
No
No
Confirmed
No
No
Confirmed
Confirmed
No
No

11

30 17
18
19

No
Suspected
Confirmed
Confirmed
Confirmed
Confirmed
No
Confirmed
Confirmed
No
Confirmed
Suspected
Confirmed
Suspected
Confirmed
Confirmed
Confirmed
Confirmed

20
21
22 and 23
35 24

No
Confirmed
Confirmed
No

No
Confirmed
Confirmed
No

No

No

15

Farm

2
4

20

25

7
8 and 9
10
11
12
13
14
15
16

25

Total No.
horses
sampled

Sera prevalence

13
9
9
11
14

15
15
9
12
15
10
14
26
15
15
9
15
15
15
11
15

15
12
2
11
24
10

15
16
7
14
29
15

73.3%
20.0%
100.0%
58.3%
68.7%
90.0%
14.3%
61.5%
60.0%
66.7%
55.6%
86.7%
60.0%
60.0%
100.0%
93.3%
100.0%
75.0%
28.6%
78.6%
82.8%
66.7%

15

53.5%

9
7
10
9
2
16
9
10

Farm specific seroprevalences ranged from 14.3-100%
ELISA= enzyme-linked immunosorbent assay.
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with marked increases in seroconversion during the months
of October 2010 and January 2011. As shown in FIG. 4, the
majority of the seropositive animals for a givenmonthhadEU
values in the range of55-119 EU. Beginning in October, there
was an increase in the frequency of high titers (;;:120 EU)
paralleling the increase in seroconversions noted in FIG. 3.
Serological results from individual farms including past
EPE status of the farm, EPE status during the study period and
calculated seroprevalence for L. intracellularis are shown in
Table 1 below.
A total of 8 farms had confirmed cases of EPE during the
study period and no farms had suspected but unconfirmed
cases. Seven of these farms had already been classified as
having previously confirmed cases of EPE and one had previously had suspected cases of EPE. Farms without a recent
history of EPE had no cases during the study period. Calculated farm-specific seroprevalences ranged from 14.3% to
100%. FIG. 5 shows the monthly seroconversionrate grouped
by recent EPE history. Whereas those farms with a recent
history of EPE (confirmed and suspected) had some horses
seroconvert each month, the farms with no recent history of
EPE (none) experienced several months in which zero or one
horse seroconverted. Table 2 shows the overall average seraprevalence as well as the average positive and maximum titer
values obtained from farms grouped by recent EPE status.
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TABLE2
Average seroprevalence, positive enzyme-linked immunosorbent assay
(ELISA) units (EU) and maximum EU grouped by equine proliferative
enteropathy CEPE) history
Previous EPE cases

Average seroprevalence

Average positive EU

Average max EU

Confirmed
Suspected
None

76.3%* (55.6-100%)
55.6% (20-86.7%)
53.1% (14.3-73.3%)

228.1 (85.5-378.9)
218.0 (59.7-326.2)
123.9** (59.5-175.6)

1683.4 (193.8-4312.3)
1604.6 (62.2-3319.4)
453.9*** (55.6-904.1)

*P < 0.05,
**P < 0.079,
***P < 0.056.

Those farms with a confirmed history of EPE had significantly (P<0.001) higher average seroprevalences compared
with those with suspected or no recent cases of EPE. Additionally, the average EU (P=0.079) and average maximum
EU values (P=0.056) were found to be lower on farms with no
recent history ofEPE cases compared with the other groups.
Moreover, the range of maximum titers is much smaller for
the farms with no recent EPE cases.
Discussion
An ELISA method was used to characterize the serological
response of Thoroughbred weanlings to L. intracellularis on
central Kentucky farms. This ELISA method used column
chromatography purified L. intracellularis, thus optimizing
reproducibility, as evidenced by an overall intra-assay CV of
6.73 and inter-assay CV of 9.60. Using this method, farmspecific seroprevalences ranged from 14.3 to 100%. As such,
these results are comparable with a past screening study in the
central Kentucky region that used the IPMA method and
showed an EPE endemic farm to have a seroprevalence of
approximately 60% while a nonendemic farm had a seraprevalence of 17% (Page eta!. 2011 b).
Not surprisingly, seroprevalences corresponded well with
the past history ofEPE cases on the farms. Significant difference between groups based on recent EPE history was seen
with respect to average seroprevalence. Additionally, farms
with no recent clinical cases of EPE had both lower average
EU and average maximum EU values for their positive
samples. One possible explanation is that farms with no history ofEPE cases probably had lower environmental burdens
of L. intracellularis resulting in fewer horses being exposed
to the bacterium (lower seroprevalence) and less antigenic
stimulation per exposure (lower EU values). Evidence for this
assertion is provided by the nonendemic farm from the previous study (Page eta!. 2011 b), which is also represented in
the current study (Farm 15). While originally considered
nonendemic, the farm has since reported suspected cases of
EPE and was re-classified for the purpose of this study.
Accordingly, the farm's seroprevalence was found to be 60%
with an average positive EU of326.2 and a maximum EU of
3319.4.
Given that the epidemiology of EPE remains poorly
defined, these data begin to indicate that relative burdens of L.
intracellularis in the environment may explain why certain
farms have an endemic problem with EPE.
Monitoring ofweanlings by the enrolled farms ultimately
identified 8 farms with confirmed cases of EPE during the
study period from August 2010 to February 2011. Perhaps not
surprisingly these 8 farms represented only those with prior
confirmed or suspected cases ofEPE (7 and 1, respectively).
While definitive ante mortem diagnosis ofEPE remains controversial, elevated L. intracellularis-specific antibody levels
are commonly identified in clinically affected horses (Frazer
2008; Page et a!. 2011 b). These confirmed cases likewise
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exhibited an increased antibody response, as was also
detected in the L. intracellularis-challenged weanlings (Page
eta!. 2011a), using this ELISA. While previous reports from
the central Kentucky region suggest a single peak of exposure
occurring during late fall/early winter (Frazer 2008; Page et
a!. 2011 b), new evidence shows bimodal exposure occurring
both in the fall and winter. These results correspond directly
with anecdotal evidence indicating a large increase in the
number of cases of EPE in this area during the months of
January and February 2011. The reason for this increased
incidence ofEPE has yet to be elucidated. Possible explanations include changes in weather patterns, changes in management and increased exposure to the unknown reservoir,
which could include clinically or subclinically affected
horses. With respect to these possibilities, it should be noted
that the summer and fall of 2010 experienced less rainfall
when compared with average amounts for the region. Additionally, there were lower daily temperatures starting in
November with increased amounts of both rain and snow,
beyond what is normal for central Kentucky during the early
winter months.
While the ELISA method affords ease of use and reliability, the establishment of a cut-off value to separate negative
and positive samples is critical. The current positive cut-off
(;,;55 EU) utilized the average EU plus 3 s.d. from values
obtained for nonchallenged weanlings, reported elsewhere
(Page eta!. 2011a), and differentiated between known seropositve and seronegative horses. Twelve field cases evaluated
using the ELISA had high levels of L. intracellularis-specific
antibodies, equalling or surpassing those EU detected in the
experimentally challenged weanlings. Also noted were several nonclinically affected weanlings with markedly elevated
EU values. These could be indicative of a successful immunological response to infection or a subclinical case that was
not detected by the farm; both situations were observed in the
previous challenge study (Page eta!. 2011a). As such, these
findings provide further evidence that the new ELISA successfully detects antibodies to L. intracellularis in clinical
and nonclinically affected horses.
There were 2 inherent limitations with the design of this
study. First, there was an overrepresentation of farms with
confirmed or suspected cases of EPE in the data set. This
likely reflected the fact that those farms with a prior history of
what they consider to be a frustrating disease were more
willing to participate and provide data. Additionally, the
stigma associated with this disease in central Kentucky may
have contributed to the large number of farms that declined to
participate due to fears that their status with respect to L.
intracellularis and EPE would become public. As such, the
overall seroprevalence of 68% should not be considered representative of the equine population in this region without
further, randomised sampling. Nevertheless, 20% of the
horses surveyed came from farms with no recent history of
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EPE and we reported both farm-specific and group-specific
seroprevalences. The other limitation and potential source for
error revolves around the possibility of cross-reaction of this
ELISA with other bacteria. Phylogenetic studies have found
that while L. intracellularis appears to be a member of unique
pathogens (Dale eta!. 1998), more recent work has shown L.
intracellularis shares similarities with some rickettsial families (Schmitz-Esser et a!. 2008). As such, potential crossreactivity between other organisms cannot be excluded without further testing. However, work to validate the ELISA
from which the method reported here was adapted failed to
detect any cross-reactivity between L. intracellularis and
related bacterial species (Wattanaphansak et a!. 2008).
By screening a large population of central Kentucky Thoroughbreds using a newly validated and equine-adapted
ELISA, a high seroprevalence for L. intracellularis-specific
antibodies was detected with variable farm-specific seraprevalences. Previous history ofEPE on the farms was associated with significant differences in average seroprevalence
indicating lower levels of exposure are present on farms with
no history of EPE. Additionally, a bimodal, seasonal distribution of exposure was documented. The high farm-specific
seroprevalences and bimodal distribution of exposure to L.
intracellularis were unexpected and suggest that farms with a
previous history of EPE remain at risk due to heightened
exposure levels beyond early winter, as has been suggested
previously.
It will now be clear to one of ordinary skill in the art that the
present method and system have features and advantages over
prior techniques including sensitivity and specificity. Variations to the specific process conditions and experimental conditions described herein may be modified or substituted as
appropriate and understood by one of ordinary skill in the art,
consistent with the present disclosure. This includes modification of the ELISA procedure to incorporate other speciesspecific reagents such that the ELISA can test samples originating from a variety of other species including, but not
limited to, swine, hamsters, rabbits, mice, rats, non-human
primates, human, raccoons, birds and insects.
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The invention claimed is:
1. A method for testing an exposure to a Lawsonia intracellularis in a subject, said method comprising:
purifYing whole Lawsonia intracellularis from host cells
and host debris using ion-exchange chromatography on
whole intact L. intracellularis produced in or on a suit-

able medium, wherein purifYing whole L. intracellularis
comprises purifYing whole L. intracellularis cells first
using centrifugation prior to the ion-exchange chromatography; and
adhering the purified L. intracellularis on a suitable material to form an antigen substrate, said substrate adapted
for determining whether a subject produces L. intracellularis-specific antibodies against the antigen, and
thereby for indicating L. intracellularis exposure or
infection in the subject.
2. Themethodofclaim 1, further comprises growingtheL.
intracellularis in or on the suitable medium.
3. The method of claim 1, wherein the ion-exchange chromatography is diethylaminothyl cellulose (DEAE) chromatography.
4. The method of claim 1, wherein the suitable material is
an enzyme-linked immunosorbent assay (ELISA) plate.
5. The method of claim 1, further comprising introducing a
serum sample from a subject to the antigen substrate to determi~e w~ether ~he serum contains L. intracellularis-specific
antJbod1es agamst the antigen.
6. The method of claim 4, further comprising centrifuging
a blood sample from the subject to produce the serum.
7. A method for diagnosing a L. intracellularis infection or
exposure in a subject, said method comprising:
acquiring a serum sample from a subject;
introducing the serum sample to an antigen substrate comprising purified L. intracellularis, produced from host
cells and host debris using ion-exchange chromatography on whole L. intracellularis, adhered to a suitable
material, wherein the purified L. intracellularis are
whole L. intracellularis whole cells produced by first
centrifugation of L. intracellularis host cells and pathogen host debris prior to the ion-exchange; and
detecting a presence of L. intracellularis-specific antibodies in the serum against the antigen substrate bound to
the antigen substrate, thereby indicating a L. intracellularis exposure or infection in the subject.
8. The method of claim 7, wherein acquiring the serum
sample comprises centrifuging a blood sample from the subject to produce the serum.
9. The method of claim 7, wherein the ion-exchange chromatography comprises DEAE chromatography.
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